

April 16, 2012

Ajinomoto Pharmaceuticals Co., Ltd.

Taiho Pharmaceutical Co., Ltd.

Distributor change for Lentinan I.V. Infusion 1 mg “Ajinomoto”, an anti-tumor agent

Ajinomoto Pharmaceuticals Co., Ltd. (President, Tomoyasu Toyoda; Headquarters, Chuo-ku, Tokyo; hereinafter “Ajinomoto Pharmaceuticals”) and Taiho Pharmaceutical Co., Ltd. (President, Masayuki Kobayashi; Headquarters, Chiyoda-ku, Tokyo; hereinafter “Taiho”) announced today that the two companies have agreed to terminate Taiho’s distributorship for Lentinan I.V. Infusion 1 mg “Ajinomoto”, an anti-tumor agent (nonproprietary name: lentinan), as of June 30, 2012. Ajinomoto Pharmaceuticals is the owner of manufacture and marketing authorization of the product and, given the expiration of distributorship agreement between the two companies, Ajinomoto Pharmaceuticals undertakes the distribution from July 1st, 2012.

Lentinan I.V. Infusion 1 mg “Ajinomoto” is a high molecular weight glucan with immunoadjuvant effects that is obtained by hot water extract from shiitake mushroom. Since the launch in April 1986, Lentinan I.V. Infusion 1 mg “Ajinomoto” has been used in treatment indicated for “prolongation of survival time by add-on to oral tegafur in patients with unresectable or recurrent gastric carcinoma”.

Ajinomoto Pharmaceuticals aims to maximize the product value of Lentinan I.V. Infusion 1 mg “Ajinomoto” to contribute to increasing patient’s quality of life.

END

Contact	
Ajinomoto Pharmaceuticals Co., Ltd. Corporate Planning Dept. TEL: +81-(0)3-6280-9802 FAX: +81-(0)3-6280-9912	Taiho Pharmaceutical Co., Ltd. PR Dept. TEL: +81-(0)3-3293-2878 FAX: +81-(0)3-3294-4532